STOCK Tg(I12b-cre/ERT2,-ALPP)37Fsh/J

Stock number: 014600
Research areas: Research Tools

Description

These transgenic mice express a tamoxifen-inducible Cre recombinase under the control of the mouse I12b enhancer element of Dlx1/2, and may be useful for generating temporal conditional mutations for studying gain or loss of function and/or fate mapping in Dlx1/2-expressing forebrain tissues, including interneurons of the olfactory bulb and neocortex.

Detailed description

These transgenic mice have a tamoxifen inducible Cre-mediated recombination system driven by the mouse Dlx1/2, distal-less homeobox 1, distal-less homeobox 2, forebrain enhancer/ promoter (I12b). The transgene insert contains a fusion product involving Cre recombinase and a mutant form of the mouse estrogen receptor ligand binding domain, and the human placental alkaline phosphatase (ALPP or PLAP). The mutant mouse estrogen receptor does not bind natural ligand at physiological concentrations but will bind the synthetic ligand, 4-hydroxytamoxifen. Restricted to the cytoplasm, the Cre/ESR1 protein can only gain access to the nuclear compartment after exposure to tamoxifen. When crossed with a strain containing loxP site flanked sequences, the flanked sequences will be deleted in the cre-expressing tissues in the offspring upon administration of tamoxifen. Tamoxifen administration induces Cre recombination in the ventral telencephalon and diencephalon as early as embryonic day 10.5 and in the olfactory bulb interneurons as early as embryonic day 15.5. Inducible recombinase activity occurs in olfactory bulb interneuron precursors throughout adulthood. The expression pattern of the transgene is similar to the endogenous forebrain expression pattern of Dlx1/2 as detected by alkaline phosphatase, placental (PLAP) histochemical analysis. Hemizygous mutant mice are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. The Donating Investigator has not attempted to make the strain homozygous.

Development

A targeting construct containing sequence encoding cre/ESR1 (CreERT2) under the control of the mouse Dlx1/2, distal-less homeobox 1, distal-less homeobox 2, forebrain enhancer/ promoter (I12b), an internal ribosomal entry sequence (IRES), the human ALPP, alkaline phosphatase, placental, (PLAP) gene, and SV40 polyadenylation site sequence, was microinjected into FVB/N donor eggs. Founder line 37 was subsequently established. The transgenic mice were then crossed to outbred Swiss Webster mice. Upon arrival at The Jackson Laboratory, the mice were crossed to FVB/NJ (Stock No. 001800) at least once to establish the colony.

Allele

Symbol: Tg(I12b-cre/ERT2,-ALPP)37Fsh
Name: transgene insertion 37, Gordon Fishell
MGI accession ID: MGI:5140608
Generation method: Transgenic
Attributes: Recombinase-expressing; Inducible
Marker symbol: Tg(I12b-cre/ERT2,-ALPP)37Fsh
Marker name: transgene insertion 37, Gordon Fishell
Chromosome: UN
Strain of origin: FVB/N
Expressed genes: cre,cre recombinase,bacteriophage P1; ESR1,estrogen receptor 1,human; ALPP,alkaline phosphatase, placental,human
Site of expression: Tamoxifen administration induces Cre recombination in the ventral telencephalon and diencephalon as early as embryonic day 10.5 and in the olfactory bulb interneurons as early as embryonic day 15.5.
Molecular note: A targeting construct containing sequence encoding xre/ERT2 under the control of the mouse Dlx1/2, distal-less homeobox 1, distal-less homeobox 2, forebrain enhancer/ promoter, I12b, with an internal ribosomal entry sequence (IRES), followed by the human placental alkaline phosphatase gene (ALPP), and SV40 polyadenylation site sequence, was microinjected into FVB/N donor eggs. Founder line 37 was subsequently established.